Bristol-Myers Squibb Company (BMY) Q1 2018 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Up 0.54%

Bristol Myers Squibb's earnings report shows a solid EPS beat, which contributed to a slight increase in stock price. The positive surprise indicates that the company is performing better than expected in terms of profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.94	N/A	+10.46%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's strategic direction. They emphasized the importance of innovation and maintaining a strong pipeline.

Management highlighted strong performance in key therapeutic areas.

They noted ongoing investments in research and development to drive future growth.

Bristol Myers Squibb Beats on EPS, Stock Up 0.54%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Up 0.54%

Key numbers

Management commentary